The ISCHEMIA trial found no evidence of reduction in MI and death with an initial invasive strategy compared with an initial conservative strategy. However, a companion publication did report significant improvements in health status. How do we sort through the results of this trial, does it provide more questions than answers? Where do we go from here?
This interventional CVCT Forum session, on Sunday, December 6th, will also cover the left main coronary disease debacle, the significance of periprocedural MI, and haemodynamic support. This session will be chaired by Dr. George Dangas, and Dr. Michael Gibson. Dr. Dangas is Director of Cardiovascular Innovation at The Mount Sinai Hospital in New York, USA. Dr. Gibson is an interventional cardiologist, at the Beth Israel Deaconess Medical Center in Boston MA, USA, and the founder of PERFUSE, an academic research organization providing clinical trial management services.
This session will look at the impact of the ISCHEMIA results on the field, with a presentation from one of the key trial investigators, Dr. Sripal Bangalore of the New York University Grossman School of Medicine, in New York, USA. Joining our co-chairs are: Roxana Mehran (New York, USA), Sunil Rao (Durham, USA), and Holger Thiele (Leipzig, GER).
The session and the moderated multi-stake holders debate will include additional points of view from industry (Chuck Simonton, from Abiomed, USA, maker of the Impella heart pump), and regulatory representatives (Lydia Glaw from the US FDA).